Business Context and Reporting Period
This Form 8-K is a current report filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on March 2, 2022. The filing discloses the appointment of a new Chief Financial Officer and the resignation of the previous principal financial officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- New CFO Base Salary: $450,000 per year.
- Targeted Cash Bonus: 40% of base salary (performance-dependent).
- Signing Bonus: $170,000 (one-time).
- Relocation Assistance: $50,000 per quarter for 12 months.
- Stock Option Grant: 350,000 shares (25% vesting after 12 months, monthly thereafter for 3 years).
Material Changes
Executive Leadership Changes:
- Alethia Young was appointed as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective April 1, 2022.
- Philip P. Gutry will resign from his roles as Head of Finance & Investor Relations, Principal Financial Officer, and Principal Accounting Officer effective April 1, 2022. He will continue to serve as Chief Business Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary contingency noted is the transition of financial leadership responsibilities effective April 1, 2022. The employment agreement is at-will, and bonus payments are contingent on pre-established performance goals.
Investor Verification Checklist
- Verify the exact start date of Alethia Young (April 1, 2022) and the immediate impact on financial reporting responsibilities.
- Confirm the total potential cash compensation for the first year, including the signing bonus and pro-rated relocation assistance.
- Review the vesting schedule for the 350,000 stock options to understand dilution implications.
- Check the full text of the Offer Letter and Severance Plan referenced in the filing for additional terms.